Eledon Pharmaceuticals (ELDN) Net Cash Flow (2013 - 2026)

Eledon Pharmaceuticals' Net Cash Flow history runs 14 years deep, the most recent figure standing at -$16.7 million for Q1 2026.

• Quarterly Net Cash Flow fell 38.19% year-over-year to -$16.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$2.3 million (down 182.51% YoY) and the FY2025 annual result came in at $2.3 million, down 85.83% from the prior year.
• Net Cash Flow was -$16.7 million for Q1 2026 at Eledon Pharmaceuticals, down from $19.1 million in the prior quarter.
• Across five years, Net Cash Flow topped out at $20.4 million in Q2 2024 and bottomed at -$37.3 million in Q3 2023.
• A 5-year average of -$4.8 million and a median of -$6.2 million in 2022 frame the typical range for Net Cash Flow.
• Annual changes were most pronounced in 2024 — Net Cash Flow jumped 1360.11% — and 2025, when it sank 1255.61%.
• Eledon Pharmaceuticals' Net Cash Flow stood at -$9.5 million in 2022, then soared by 109.97% to $945000.0 in 2023, then soared by 1360.11% to $13.8 million in 2024, then jumped by 38.71% to $19.1 million in 2025, then tumbled by 187.03% to -$16.7 million in 2026.
• Business Quant data shows ELDN's Net Cash Flow at -$16.7 million in Q1 2026, $19.1 million in Q4 2025, and -$2.1 million in Q3 2025.